NYSEAMERICAN:BPMX Biopharmx (BPMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Biopharmx Stock (NYSEAMERICAN:BPMX) Get Biopharmx alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume336,508 shsAverage Volume2.15 million shsMarket Capitalization$111.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioPharmX Corporation was a specialty pharmaceutical company focused on developing and commercializing treatments for dermatological conditions. Its work centered on topical therapies intended to address unmet needs in acne and other skin disorders. The company’s primary product candidate was BPX-01, a topical minocycline gel developed for the treatment of moderate-to-severe acne vulgaris. BioPharmX also pursued delivery technologies designed to improve the topical administration of pharmaceutical ingredients while potentially reducing some limitations associated with oral therapies. BioPharmX was based in the United States and operated primarily in the dermatology pharmaceutical market. The company later underwent corporate changes, and its operations and assets were associated with Journey Medical Corporation. Because BioPharmX is no longer an active standalone public company under its former identity, current information about its leadership, products and commercial operations is limited.AI Generated. May Contain Errors. Read More Receive BPMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BPMX Stock News HeadlinesTMBRQ Trex Wind-down, Inc.April 19, 2024 | seekingalpha.comTrex Wind Down Inc (TMBRQ)April 17, 2024 | investing.comBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th.September 28 at 1:00 AM | Paradigm Press (Ad)BioPharmX (BPMX) Stock Soars on Potential 'Breakthrough' Acne TreatmentJuly 8, 2023 | thestreet.comForm 424B5 Timber Pharmaceuticals, - StreetInsider.comOctober 3, 2022 | streetinsider.comOutlook on the Acne Treatment Global Market, to 2027 - Rising Public Knowledge of Cosmetic Acne Treatments is Driving Growth - Yahoo FinanceSeptember 22, 2022 | finance.yahoo.comGlobal Acne Treatment Market, By Therapeutic Class, By Formulation, By Type, By Acne Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 - GlobeNewswireJuly 19, 2022 | globenewswire.comTimber Pharmaceuticals, Inc. (TMBR) Stock Price Today, Quote & News - Seeking AlphaJuly 17, 2022 | seekingalpha.comSee More Headlines BPMX Stock Analysis - Frequently Asked Questions How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share for the quarter, topping the consensus estimate of ($2.64) by $0.96. When did Biopharmx's stock split? Biopharmx's stock reverse split on the morning of Tuesday, May 19th 2020.The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Biopharmx? Shares of BPMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biopharmx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Hawkins (HWKN), Novavax (NVAX) and Protalix BioTherapeutics (PLX). Company Calendar Last Earnings12/10/2019Today9/28/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CIKN/A Webwww.biopharmx.com Phone+1-650-8895020FaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,278,000Free FloatN/AMarket Cap$111.86 million OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSEAMERICAN:BPMX) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biopharmx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Biopharmx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.